The case concerns three Takeda patents for Actos that were set to expire in January 2011, and two follow-up patents that were to expire in June 2016. Read more
A former GlaxoSmithKline (GSK) executive, who is now a whistleblower, told a Massachusetts federal court last month that Takeda Pharmaceutical executives admitted to a kickback scheme “for t... Read more
A $2.3 million verdict was returned against Takeda Pharmaceuticals Inc. last month in an Actos case. A Philadelphia jury concluded that the diabetes drug had been a significant cause of a re... Read more
U.S. District Judge Rebecca Doherty has rejected the attempt by Takeda Pharmaceutical Co. and Eli Lilly & Co. to get the combined $9 billion punitive-damage award returned by a jury thro... Read more
Blue Cross and Blue Shield of Massachusetts Inc. has filed a number of subrogation actions in the Louisiana multidistrict litigation (MDL) over the bladder cancer risks carried by Takeda Pha... Read more
A federal jury in Lafayette, La., last month ordered Takeda Pharmaceutical Co., based in Osaka, Japan, and its partner, Eli Lilly & Co, based in Indianapolis, Ind., to pay a combined $9... Read more
Beasley Allen lawyers continue to pursue Actos claims on behalf of individuals who have been diagnosed with bladder cancer after using Actos to treat their type 2 diabetes. Andy Birchfield a... Read more
Lawyers at Beasley Allen continue to evaluate and file claims involving bladder cancer during or following usage of Actos, Actoplus Met, Actoplus Met XR, and/or Duetact. Manufactured by Tak... Read more
As mentioned above, lawyers in our Mass Torts Section are currently investigating and filing claims on behalf of individuals who have been diagnosed with bladder cancer following long-term e... Read more
A federal medical advisory panel recommended last month that the diabetes drug, Avandia, should either be withdrawn from the market or have sales severely restricted because it increases the... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.